兽药活性成分 (API) 市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球兽用活性药物成分 (API) 市场价值达79亿美元，预计到2034年将以7.4%的复合年增长率成长，达到160亿美元。这一稳定成长主要得益于宠物饲养量的增加、动物健康意识的提升以及兽医技术的进步。消费者越来越倾向于以与自身同等程度的医疗保健来对待动物，这直接影响了对优质兽药的需求。人畜共通传染病的日益普及也加剧了对可靠治疗方法的需求，使得兽用API在安全有效药物开发中比以往任何时候都更加重要。

兽用API是用于配製治疗、控製或预防动物疾病药物的核心成分。这些成分对牲畜和伴侣动物都至关重要，可用于广泛的治疗应用。随着全球畜牧业产量和宠物收养量的增加，对符合良好生产规范 (GMP) 等监管标准的高品质API的需求持续成长。 API具有成本效益，因为它们适合大量生产，确保价格效率且不影响品质。它们还允许製药商针对特定物种和剂型定製药物，包括口服、注射和饲料配方。 API的灵活性、经济性和高一致性使其成为生产有效兽药不可或缺的一部分。

根据API类型，市场细分为抗寄生虫药、抗感染药、疫苗、生物製剂、荷尔蒙、抗发炎药物和其他API。其中，抗寄生虫药物占据市场主导地位，2024年收入达20亿美元，预计到2034年将达到42亿美元，复合年增长率为7.9%。动物寄生虫病（例如心丝虫、跳蚤和胃肠道感染）发病率的不断上升，推动了对靶向抗寄生虫治疗的需求，这反过来又推动了该领域对高效优质API的需求。

根据合成类型，市场可分为化学型 API、生物型 API 和高效能 API（HPAPI）。化学型 API 凭藉其成本效益高、保质期长且易于量产，在 2024 年占据了 58.2% 的最大份额。这些 API 广泛用于治疗感染和发炎等一系列疾病，并作为许多兽药的基础成分。其药理特性使其适合与其他成分组合，从而增强治疗效果。化学合成技术的不断改进也支持了这些 API 在各种兽药应用中的广泛应用。

就动物类型而言，市场细分为家畜和伴侣动物。伴侣动物市场预计将以7.6%的复合年增长率成长，到2034年达到107亿美元。这一增长归因于宠物人性化趋势的日益增强，以及宠物主人在预防性和治疗性医疗保健方面的投资意愿。随着宠物照护日益专业化和精细化，对生物製剂、荷尔蒙和消炎药等先进兽药的需求持续成长。

根据服务类型，市场进一步细分为内部製造和合约外包。内部製造在2024年占据最大市场份额，为55.3%，预计到2034年将达到87亿美元。该细分市场受益于诸如增强的品质保证、更低的生产成本以及更快的药物开发上市时间等优势。拥有内部API生产能力的公司能够更好地管理库存并快速适应市场需求，从而在快速发展的兽药领域占据竞争优势。

从地区来看，北美在2024年的收入最高，为31亿美元，预计到2034年将攀升至60亿美元，复合年增长率为7.1%。该地区的领先地位得益于其广泛的宠物饲养、对动物健康问题的高度关注以及强大的兽医保健基础设施。随着越来越多的消费者寻求宠物和牲畜的先进治疗方案，优质API的需求持续成长，从而巩固了北美在全球市场的主导地位。

积极推动市场发展的关键参与者包括 AMGIS Lifescience、Abino Pharma、BOC Sciences、Hikal、Huvepharma (Olon)、勃林格殷格翰、Indukern Group、NGL Fine-Chem、Menadiona、Ofichem Group、齐鲁製药、Sequent Scientific、Procyon Life Sciences、Menadiona、Ofichem Group、齐鲁製药、Sequent Scientific、Procyon Life Sciences、JSUA、VSUA、VSUk、JSUA、JSUA、JSUA、JSUA、JSUA、JSUA、JSUA、JSUA、JSUA、JSUA、JSUA、JSUA、J、Avet.这些公司致力于增强生产能力，拓展产品组合，并满足全球对兽用 AP 日益增长的需求。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 宠物拥有率上升
    • 提高动物健康的主动性和意识
    • 药物製剂技术不断进步
    • 人畜共通传染病发生率上升
    • 扩大外包服务
  • 产业陷阱与挑战
    • 严格的监管审批
    • 研发成本高
• 成长潜力分析
• 监管格局
• 波特的分析
• PESTLE 分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按 API 类型，2021 年至 2034 年

• 主要趋势
• 抗感染药物
• 抗寄生虫药
• 疫苗
• 荷尔蒙
• 生物製剂
• 消炎剂
• 其他 API 类型

第六章：市场估计与预测：依合成类型，2021 年至 2034 年

• 主要趋势
• 基于化学的 API
• 生物原料药
• 高效能 API (HPAPI)

第七章：市场估计与预测：依动物类型，2021 年至 2034 年

• 主要趋势
• 伴侣动物
• 牲畜

第八章：市场估计与预测：按服务类型，2021 年至 2034 年

• 主要趋势
• 内部
• 合约外包
  • 合约开发
  • 合约製造

第九章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Abino Pharma
• AMGIS Lifescience
• BOC Sciences.
• Boehringer Ingelheim
• Hikal
• Huvepharma
• Indukern Group
• Menadiona
• NGL Fine-Chem
• Ofichem Group
• Procyon Life Sciences
• Qilu Pharmaceutical
• Sequent Scientific
• SUANFARMA
• Vetpharma
• Veyx-Pharma

The Global Veterinary Active Pharmaceutical Ingredients (API) Market was valued at USD 7.9 billion in 2024 and is estimated to grow at a CAGR of 7.4% to reach USD 16 billion by 2034. This steady growth is largely fueled by increasing pet ownership, rising awareness about animal health, and advancements in veterinary technologies. Consumers are becoming more inclined to treat animals with the same level of healthcare they expect for themselves, which has directly impacted the demand for quality veterinary medications. The growing prevalence of zoonotic diseases has also intensified the urgency for reliable treatments, making veterinary APIs more crucial than ever in the development of safe and effective drugs.

Veterinary APIs are core ingredients used to formulate medicines that treat, manage, or prevent diseases in animals. These ingredients are essential for both livestock and companion animals, serving a wide range of therapeutic applications. With the increase in global livestock production and pet adoption, there is a consistent need for high-quality APIs that meet regulatory benchmarks such as Good Manufacturing Practices (GMP). APIs are cost-effective due to their compatibility with bulk production, ensuring price efficiency without compromising quality. They also allow pharmaceutical manufacturers to tailor drugs for specific species and dosage forms, including oral, injectable, and feed-based solutions. The flexibility, affordability, and high consistency of APIs make them integral to producing effective veterinary treatments.

The market is segmented by API type into anti-parasitics, anti-infectives, vaccines, biologics, hormones, anti-inflammatories, and other APIs. Among these, anti-parasitics dominated the market with a revenue of USD 2 billion in 2024 and are forecasted to reach USD 4.2 billion by 2034, recording a CAGR of 7.9%. The increasing incidence of parasitic diseases in animals, such as heartworms, fleas, and gastrointestinal infections, is driving the demand for targeted anti-parasitic treatments, which in turn pushes the need for robust and quality APIs in this segment.

Based on synthesis type, the market is categorized into chemical-based APIs, biological APIs, and highly potent APIs (HPAPIs). Chemical-based APIs held the largest share of 58.2% in 2024 due to their cost-efficiency, long shelf life, and ease of mass production. These APIs are widely used in treating a range of conditions like infections and inflammation and serve as the foundational building blocks for many veterinary drugs. Their pharmacological properties make them suitable for combination with other ingredients, enhancing their therapeutic efficacy. Continuous improvements in chemical synthesis technologies are also supporting the increased adoption of these APIs across various veterinary applications.

In terms of animal type, the market is segmented into livestock animals and companion animals. The companion animals segment is projected to grow at a CAGR of 7.6%, reaching USD 10.7 billion by 2034. This growth is attributed to the increasing trend of pet humanization and the willingness of pet owners to invest in preventive and therapeutic healthcare. Demand for advanced veterinary pharmaceuticals such as biologics, hormones, and anti-inflammatory drugs continues to rise as pet care becomes more specialized and sophisticated.

The market is further divided by service type into in-house manufacturing and contract outsourcing. In-house manufacturing held the largest market share at 55.3% in 2024 and is projected to reach USD 8.7 billion by 2034. This segment benefits from advantages like enhanced quality assurance, lower production costs, and faster time-to-market for drug development. Companies with in-house API production capabilities are better positioned to manage inventory and adjust to market demands quickly, giving them a competitive edge in the fast-evolving veterinary pharmaceutical space.

Regionally, North America accounted for the highest revenue of USD 3.1 billion in 2024 and is expected to climb to USD 6 billion by 2034, growing at a CAGR of 7.1%. The region's leadership is reinforced by widespread pet ownership, high awareness of animal health issues, and a strong veterinary healthcare infrastructure. The demand for premium-quality APIs continues to increase as more consumers seek advanced treatments for both pets and livestock, supporting North America's dominant position in the global market.

Key players actively contributing to the market landscape include AMGIS Lifescience, Abino Pharma, BOC Sciences, Hikal, Huvepharma (Olon), Boehringer Ingelheim, Indukern Group, NGL Fine-Chem, Menadiona, Ofichem Group, Qilu Pharmaceutical, Sequent Scientific, Procyon Life Sciences, SUANFARMA, Vetpharma, and Veyx-Pharma. These companies are focused on strengthening their manufacturing capabilities, expanding their product portfolios, and meeting rising global demand for veterinary APIs.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising pet ownership rate
    • 3.2.1.2 Growing initiative and awareness for animal health
    • 3.2.1.3 Growing technological advancements in drug formulations
    • 3.2.1.4 Rising incidence of zoonotic disease
    • 3.2.1.5 Expanding outsourcing services
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory approval
    • 3.2.2.2 High R&D cost
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTLE analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By API Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Anti-infectives
• 5.3 Anti-parasitics
• 5.4 Vaccines
• 5.5 Hormones
• 5.6 Biologics
• 5.7 Anti-inflammatory
• 5.8 Other API types

Chapter 6 Market Estimates and Forecast, By Synthesis Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Chemical based API
• 6.3 Biological API
• 6.4 Highly potent API (HPAPI)

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Companion animals
• 7.3 Livestock animals

Chapter 8 Market Estimates and Forecast, By Service Type, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 In-house
• 8.3 Contract outsourcing
  • 8.3.1 Contract development
  • 8.3.2 Contract manufacturing

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abino Pharma
• 10.2 AMGIS Lifescience
• 10.3 BOC Sciences.
• 10.4 Boehringer Ingelheim
• 10.5 Hikal
• 10.6 Huvepharma
• 10.7 Indukern Group
• 10.8 Menadiona
• 10.9 NGL Fine-Chem
• 10.10 Ofichem Group
• 10.11 Procyon Life Sciences
• 10.12 Qilu Pharmaceutical
• 10.13 Sequent Scientific
• 10.14 SUANFARMA
• 10.15 Vetpharma
• 10.16 Veyx-Pharma